TY - JOUR
T1 - HIV-1 replication cycle
AU - Ferguson, Monique R.
AU - Rojo, Daniel R.
AU - Von Lindern, Jana J.
AU - O'Brien, William A.
N1 - Funding Information:
This work is supported by the James McLaughlin Fellowship Fund and by Public Health Service grants R24 59656, R01 38414, and R21 46250.
PY - 2002/9
Y1 - 2002/9
N2 - The HIV-1 is a formidable pathogen with establishment of a persistent infection based on the ability to integrate the proviral genome into chronically infected cells, and by the rapid evolution made possible by a high mutation rate and frequent recombination during the viral replication. HIV-1 has a variety of novel genes that facilitate viral persistence and regulation of HIV replication, but this virus also usurps cellular machinery for HIV replication, particularly during gene expression and virion assembly and budding. Recent success with antiretroviral therapy may be limited by the emergence HIV drug resistance and by toxicities and other requirements for successful long-term therapy. Further investigation of HIV-1 replication may allow identification of novel targets of antiretroviral therapy that may allow continued virus suppression in patients of failing current regiments, particularly drugs that target HIV-1 entry and HIV-1 integration.
AB - The HIV-1 is a formidable pathogen with establishment of a persistent infection based on the ability to integrate the proviral genome into chronically infected cells, and by the rapid evolution made possible by a high mutation rate and frequent recombination during the viral replication. HIV-1 has a variety of novel genes that facilitate viral persistence and regulation of HIV replication, but this virus also usurps cellular machinery for HIV replication, particularly during gene expression and virion assembly and budding. Recent success with antiretroviral therapy may be limited by the emergence HIV drug resistance and by toxicities and other requirements for successful long-term therapy. Further investigation of HIV-1 replication may allow identification of novel targets of antiretroviral therapy that may allow continued virus suppression in patients of failing current regiments, particularly drugs that target HIV-1 entry and HIV-1 integration.
UR - http://www.scopus.com/inward/record.url?scp=0036718421&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036718421&partnerID=8YFLogxK
U2 - 10.1016/S0272-2712(02)00015-X
DO - 10.1016/S0272-2712(02)00015-X
M3 - Review article
C2 - 12244589
AN - SCOPUS:0036718421
SN - 0272-2712
VL - 22
SP - 611
EP - 635
JO - Clinics in Laboratory Medicine
JF - Clinics in Laboratory Medicine
IS - 3
ER -